𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Nephrotic syndrome with pegylated interferon alfa 2a and ribavirin for a patient with chronic hepatitis C

✍ Scribed by Ajit Sood; Vandana Midha; Jaswinder S. Sandhu; Neena Sood; Amarjit Kaur; Rasham Mittal; Sandeep Puri

Book ID
107680838
Publisher
Springer-Verlag
Year
2010
Tongue
English
Weight
69 KB
Volume
29
Category
Article
ISSN
0254-8860

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Response to pegylated interferon alfa-2a
Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4
✍ Hesham El Makhzangy; Gamal Esmat; Mohamed Said; Maissa ElRaziky; Soheir Shouman; πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 91 KB

## Abstract The safety and efficacy of pegylated interferon (PEG‐IFN) alfa‐2a and ribavirin were studied among patients treated for genotype 4 chronic hepatitis C. Ninety‐five patients with chronic hepatitis C genotype 4 were treated with PEG‐IFN alfa‐2a (180 ¡g/week) plus ribavirin (β‰₯11 mg/kg/day)

Association of host pharmacodynamic effe
Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C
✍ Raymond T. Chung; Fred F. Poordad; Tarek Hassanein; Xiaolei Zhou; Ellen Lentz; A πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 773 KB

Patients receiving therapy for chronic hepatitis C virus (HCV) infection frequently experience cytopenias and weight loss. We retrospectively assessed the pharmacodynamic effects of pegylated interferon (PEG-IFN) alfa-2a and ribavirin by evaluating the relationship between changes in hematologic par